Aviance Capital Partners LLC Sells 54 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Aviance Capital Partners LLC lowered its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,629 shares of the company’s stock after selling 54 shares during the quarter. Aviance Capital Partners LLC’s holdings in HCA Healthcare were worth $3,101,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC grew its holdings in shares of HCA Healthcare by 115.5% in the first quarter. Acadian Asset Management LLC now owns 3,372 shares of the company’s stock worth $1,123,000 after purchasing an additional 1,807 shares during the last quarter. Bessemer Group Inc. grew its stake in HCA Healthcare by 51.2% in the 1st quarter. Bessemer Group Inc. now owns 7,629 shares of the company’s stock valued at $2,543,000 after acquiring an additional 2,584 shares during the period. Lake Street Advisors Group LLC boosted its stake in shares of HCA Healthcare by 137.2% in the first quarter. Lake Street Advisors Group LLC now owns 2,697 shares of the company’s stock worth $900,000 after acquiring an additional 1,560 shares during the last quarter. Shell Asset Management Co. grew its holdings in shares of HCA Healthcare by 24.4% during the first quarter. Shell Asset Management Co. now owns 11,808 shares of the company’s stock worth $3,938,000 after buying an additional 2,319 shares in the last quarter. Finally, CreativeOne Wealth LLC purchased a new position in HCA Healthcare during the first quarter worth approximately $231,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at HCA Healthcare

In other news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now directly owns 52,702 shares in the company, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the transaction, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,155 shares of company stock worth $5,608,990 over the last quarter. Company insiders own 1.70% of the company’s stock.

HCA Healthcare Price Performance

NYSE:HCA opened at $335.89 on Tuesday. HCA Healthcare, Inc. has a 1-year low of $245.03 and a 1-year high of $417.14. The firm has a fifty day simple moving average of $384.12 and a 200 day simple moving average of $358.11. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The stock has a market capitalization of $85.08 billion, a PE ratio of 15.08, a P/E/G ratio of 1.32 and a beta of 1.68.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a $0.66 dividend. The ex-dividend date is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.79%. HCA Healthcare’s dividend payout ratio (DPR) is currently 11.85%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HCA shares. Truist Financial increased their price objective on shares of HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Royal Bank of Canada raised their price objective on shares of HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Friday, August 23rd. Barclays decreased their target price on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. TD Cowen dropped their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Finally, Oppenheimer upped their target price on shares of HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $385.00.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.